Literature DB >> 18823850

Extensively drug-resistant tuberculosis.

Miguel G Madariaga1, Umesh G Lalloo, Susan Swindells.   

Abstract

Extensively drug-resistant tuberculosis (XDR-TB) is defined as Mycobacterium tuberculosis infection that is resistant to isoniazid, rifampin, any fluoroquinolone, and any injectable drug (amynoglicosides or polypetides). Although initially described in South Africa, it has emerged as a global threat, and cases have been reported from several countries, including the United States. XDR-TB has emerged mainly as a consequence of previous inadequate or poorly administered treatment, from failure of the public health infrastructure. As the diagnosis of this condition requires antibiotic susceptibility confirmation, a broad network of reference laboratories and the development of faster and more accurate tests for the identification of active cases of tuberculosis are urgently required. The treatment of XDR-TB is challenging and requires the use of multiple second-line drugs and, potentially, surgery. Infection control measures do not differ from those used for susceptible cases but may require more stringent application.

Entities:  

Mesh:

Substances:

Year:  2008        PMID: 18823850     DOI: 10.1016/j.amjmed.2008.04.015

Source DB:  PubMed          Journal:  Am J Med        ISSN: 0002-9343            Impact factor:   4.965


  5 in total

1.  Pulmonary resection for extensively drug resistant tuberculosis in Kwazulu-Natal, South Africa.

Authors:  Adam Iddriss; Nesri Padayatchi; Darshan Reddy; Anu Reddi
Journal:  Ann Thorac Surg       Date:  2012-05-24       Impact factor: 4.330

2.  The burden and characteristics of tuberculosis/human immunodeficiency virus (TB/HIV) in South Korea: a study from a population database and a survey.

Authors:  Chang-Hoon Lee; Ji-Young Hwang; Dae-Kyu Oh; Mee-Kyung Kee; Eunjung Oh; Jung-Wook An; Jinhyun Kim; Heonsook Do; Hee-Jin Kim; Sung Soon Kim; Hwahyun Kim; Jeong-Gu Nam
Journal:  BMC Infect Dis       Date:  2010-03-12       Impact factor: 3.090

3.  Biochemical characterization of the Mycobacterium tuberculosis phosphoribosyl-1-pyrophosphate synthetase.

Authors:  Luke J Alderwick; Georgina S Lloyd; Adrian J Lloyd; Andrew L Lovering; Lothar Eggeling; Gurdyal S Besra
Journal:  Glycobiology       Date:  2010-11-02       Impact factor: 4.313

4.  XDR Tuberculosis: A Looming Threat.

Authors:  Vishal Sharma; Sourabh Aggarwal
Journal:  Indian J Community Med       Date:  2009-04

5.  Inhibition of nuclear factor-kappa B activation decreases survival of Mycobacterium tuberculosis in human macrophages.

Authors:  Xiyuan Bai; Nicole E Feldman; Kathryn Chmura; Alida R Ovrutsky; Wen-Lin Su; Laura Griffin; Dohun Pyeon; Mischa T McGibney; Matthew J Strand; Mari Numata; Seiji Murakami; Loretta Gaido; Jennifer R Honda; William H Kinney; Rebecca E Oberley-Deegan; Dennis R Voelker; Diane J Ordway; Edward D Chan
Journal:  PLoS One       Date:  2013-04-25       Impact factor: 3.240

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.